Treatment of COVID-19 Patients Post-Bariatric Surgery: Issues for Consideration.
As COVID-19 has been expanding rapidly around the world, the types of patients and their backgrounds vary. The substantially altered GI anatomy/physiology after bariatric surgery presents new challenges to the field of oral drug therapy. In this report we highlight issues for consideration when treating COVID-19 patients who previously underwent bariatric surgery and provide practical tools to allow optimal care of these patients. Post-bariatric absorption/pharmacokinetic changes may warrant dose adjustment, as well as the use of liquid oral dosage forms or parenteral routes of administration, if available. Realizing the potentially altered pharmacokinetics of various drugs after bariatric surgery is essential for providing optimal pharmacological therapy and overall patient care.
['Azran|Carmil|C|', 'Porat|Daniel|D|', 'Dahan|Arik|A|0000-0002-3498-3514', 'Dicker|Dror|D|']
COVID-19 bariatric surgery drug absorption pharmacotherapy